Cedars-Sinai Medical Center - UCLA School of Medicine

Samuel Oschin Comprehensive Cancer Institute

Los Angeles, CA
(888) 850-0650

Accepting patients

MagnetisMM-4

Phase 1/2 Clinical Trial Evaluating the Safety, Effectiveness and Best Dose of Elranatamab Combined with Different Anti-Cancer Therapies in Participants with Multiple Myeloma
Learn more
  • Bispecific Antibody
  • Gamma-Secretase Inhibitor
  • BCMA
  • Phase 1/2

Accepting patients

Iberdomide vs. Observation Post Ide-Cel CAR-T

Randomized Phase 2 Study of Iberdomide Maintenance Therapy Following Idecabtagene Vicleucel CAR-T in Multiple Myeloma Patients
Learn more
  • CELMoD
  • Maintenance
  • Randomization
  • Phase 2

Accepting patients

Autologous Stem Cell Transplant Post CAR-T

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/​Refractory Hematological Malignancies
Learn more
  • Autologous Stem Cell Transplant
  • CAR T Cell
  • BCMA
  • Phase 1

Not yet accepting

QXL138AM

A First-in-human Phase 1a/1b Study to Evaluate Safety and Tolerability of QXL138AM in Patients With Locally Advanced Un-resectable and/or Metastatic Solid Tumors and Multiple Myeloma
Learn more
  • CD138
  • Phase 1

Accepting patients

DRAMMATIC

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)
Learn more
  • Monoclonal Antibody
  • CD38
  • Maintenance
  • Phase 3
2 hidden based on your filters. Show All